Anemia Clinical Trials

Find Anemia Clinical Trials Near You

A Randomized Controlled Trial Comparing Different Graft Sources for Haploidentical Transplantation in Aplastic Anemia

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Severe aplastic anemia is a life-threatening bone marrow failure disorder. Haploidentical hematopoietic stem cell transplantation has become an important curative treatment option for patients who do not have an HLA-matched sibling donor. Traditionally, haploidentical transplantation for severe aplastic anemia uses a graft composed of granulocyte colony-stimulating factor-primed bone marrow plus peripheral blood stem cells. However, bone marrow collection is invasive and may increase donor burden. Peripheral blood stem cell collection is simpler and less invasive, but it remains unclear whether using peripheral blood stem cells alone provides similar clinical outcomes without increasing the risk of graft-versus-host disease. This multicenter, randomized, open-label, non-inferiority trial will compare granulocyte colony-stimulating factor-primed peripheral blood stem cells alone with granulocyte colony-stimulating factor-primed bone marrow plus peripheral blood stem cells as graft sources for haploidentical transplantation in patients with severe or very severe aplastic anemia. Participants will be randomly assigned in a 1:1 ratio to either graft source group. The primary outcome is the cumulative incidence of grade II-IV acute graft-versus-host disease within 100 days after transplantation. Secondary outcomes include engraftment, chronic graft-versus-host disease, infections, immune reconstitution, survival, and donor safety.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 40
Healthy Volunteers: f
View:

• Patients with newly diagnosed or relapsed severe aplastic anemia (SAA) or very severe aplastic anemia (vSAA) according to the Camitta criteria.

• SAA is defined as bone marrow cellularity \<25% and at least two of the following peripheral blood criteria: absolute neutrophil count \<0.5 × 10\^9/L, platelet count \<20 × 10\^9/L, or reticulocyte count \<20 × 10\^9/L.

• vSAA is defined as SAA with an absolute neutrophil count \<0.2 × 10\^9/L.

• Age 18 to 40 years.

• Availability of a haploidentical related donor.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

• Adequate organ function, defined as follows:

• Cardiac function: left ventricular ejection fraction ≥50% and no severe arrhythmia.

• Hepatic function: total bilirubin ≤2 times the upper limit of normal and alanine aminotransferase/aspartate aminotransferase ≤3 times the upper limit of normal.

• Renal function: creatinine clearance ≥60 mL/min.

• No active infection.

• For women of childbearing potential, a negative pregnancy test is required.

• All patients must agree to use effective contraception during the study period.

• Written informed consent provided by the patient or legal representative.

Locations
Other Locations
China
Peking university people's hospital
RECRUITING
Beijing
Time Frame
Start Date: 2026-06-15
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 180
Treatments
Experimental: G-CSF-Primed Peripheral Blood Stem Cell Graft
Participants assigned to this arm will undergo haploidentical hematopoietic stem cell transplantation using granulocyte colony-stimulating factor-primed peripheral blood stem cells alone as the graft source. Donors will receive granulocyte colony-stimulating factor mobilization, and peripheral blood stem cells will be collected by apheresis. Participants will receive the protocol-specified conditioning regimen and graft-versus-host disease prophylaxis.
Experimental: G-CSF-Primed Bone Marrow Plus Peripheral Blood Stem Cell Graft
Participants assigned to this arm will undergo haploidentical hematopoietic stem cell transplantation using granulocyte colony-stimulating factor-primed bone marrow plus peripheral blood stem cells as the graft source. Donors will receive granulocyte colony-stimulating factor mobilization, followed by bone marrow harvest and peripheral blood stem cell collection. Participants will receive the protocol-specified conditioning regimen and graft-versus-host disease prophylaxis.
Sponsors
Leads: Peking University People's Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials